Table 3.
IgG, weeks 0–3*(n=793) | Neutralisation, weeks 0–3*(n=368) | IgG, weeks 3–5*(n=1395) | Neutralisation, weeks 3–4*(n=419) | |
---|---|---|---|---|
Sex | ||||
Male (vs female) | 0·77 (0·67–0·88) | 0·7 (0·50–0·97) | 1·09 (0·92–1·28) | 0·77 (0·52–1·14) |
Age (years) | ||||
46–65·99 (vs 18–45·99) | 0·52 (0·46–0·58) | 0·57 (0·43–0·75) | 1·66 (1·43–1·93) | 1·04 (0·74–1·46) |
≥66 (vs 18–45·99) | 0·25 (0·19–0·31) | 0·28 (0·18–0·42) | 2·66 (2·00–3·53) | 0·93 (0·57–1·51) |
BMI (kg/m2) | ||||
25–29·99 (vs <25) | 0·92 (0·80–1·05) | 0·99 (0·73–1·34) | 1·14 (0·97–1·33) | 0·80 (0·56–1·14) |
≥30 (vs <25) | 1·15 (0·97–1·37) | 0·92 (0·62–1·35) | 0·91 (0·74–1·12) | 0·61 (0·39–0·96) |
Comorbidities | ||||
Hypertension | 0·99 (0·82–1·20) | 0·89 (0·59–1·34) | 0·89 (0·71–1·13) | 1·72 (1·07–2·79) |
Autoimmune disease | 0·87 (0·70–1·09) | 0·78 (0·53–1·13) | 0·94 (0·70–1·26) | 0·97 (0·61–1·55) |
Diabetes | 1·03 (0·80–1·32) | 0·83 (0·50–1·38) | 0·84 (0·62–1·14) | 0·70 (0·38–1·28) |
Lung disease | 0·74 (0·55–0·99) | 0·64 (0·36–1·14) | 1·56 (1·06–2·29) | 1·21 (0·61–2·40) |
Heart disease | 0·69 (0·49–0·96) | 0·92 (0·47–1·80) | 1·28 (0·86–1·93) | 0·64 (0·29–1·41) |
Immunosuppression† | 0·21 (0·14–0·31) | .. | 2·45 (1·35–4·45) | .. |
Data are ratios of means (95% CI) from the linear mixed analysis model. BMI=body-mass index. ..=data not available.
The inductions in IgG and neutralising antibody titres were measured 3 weeks after the first vaccination dose (first-dose effects); and between 3 and 5 weeks for IgG, or between 3 and 4 weeks for neutralising antibodies for the second-dose effects (neutralising antibodies were not assessed at 5 weeks). Week 3 refers to the administration of the second vaccination dose, and weeks 4 and 5 are the first and second weeks following the second vaccination dose, respectively.
Immunosuppression included organ transplantation; being on biologic therapy, chemotherapy, or steroids; and splenectomy.